Tejara Capital’s Accelerate Diagnostics AXDX Stock Holding History

Tejara Capital’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-13,056	Closed	-$9.15K	–	73
2025 Q1	$9.15K	Sell	13,056 -84	-0.6%	-$96	﹤0.01%	75
2024 Q4	$15.8K	Sell	13,140 -416	-3%	-$691	0.01%	54
2024 Q3	$23.2K	Sell	13,556 -58	-0.4%	-$86	0.01%	55
2024 Q2	$15.9K	Hold	13,614	–	–	0.01%	68
2024 Q1	$13.5K	Hold	13,614	–	–	0.01%	75
2023 Q4	$53.4K	Hold	13,614	–	–	0.02%	66
2023 Q3	$78.3K	Buy	+13,614	New	+$91.6K	0.04%	64
2023 Q2	–	Sell	-36,263	Closed	-$254K	–	76
2023 Q1	$254K	Buy	36,263 +10,000	+38%	+$60.1K	0.13%	72
2022 Q4	$185K	Buy	+26,263	New	+$287K	0.11%	88

Other funds holding AXDX

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

BCWM

Bartlett & Co Wealth Management Cincinnati, Ohio $7.99B AUM 20.76% 1-Year Est. Return

Tejara Capital's AXDX Position: Q2 2025 in Review

Tejara Capital sold out of Accelerate Diagnostics (AXDX) in Q2 2025, closing a stake of 13,056 shares — an estimated $9.15K sold.

Tejara Capital first reported a position in AXDX in Q4 2022 and held it in 9 quarters. The position peaked at $254K in Q1 2023. 3 funds tracked by Wall St. Rank hold AXDX as of Q2 2025.

Tejara Capital reported no remaining Accelerate Diagnostics position as of Q2 2025 after selling out during the quarter.
Tejara Capital sold 13,056 Accelerate Diagnostics shares in Q2 2025, an estimated $9.15K.
Tejara Capital first reported a position in Accelerate Diagnostics in Q4 2022 and held it in 9 quarters.
Tejara Capital's Accelerate Diagnostics position peaked at $254K in Q1 2023.
3 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2025.

Based on Tejara Capital's 13F filing for Q2 2025, filed 13 Aug 2025.